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Summary Aryl hydrocarbon hydroxylase (AHH) activity was measured in the breast tumours of 153 primary
and 17 recurrent cancer patients, and in 18 patients with benign breast tumour. All operations were carried
out in 1983-84. The cytosolic fraction was collected for steroid receptor determination, and microsomes were
separated for AHH assay from the same tissue samples. The AHH distribution was wide and highly skewed in
all groups. About 10% of the samples showed activities below detection limit. The medians and ranges for
primary cancers were 34 (<5-2683), for recurrent cancers 40 (20-239) and for benign tumours 11 (<5-37)
fmol min-' mg-' protein. After logarithmic transformation, the mean AHH activities of cancer samples
differed significantly from those of benign tumours. The logarithm of AHH activity (log AHH) correlates
positively with axillary lymph node status, and negatively with steroid receptor levels. The development of the
disease and the survival of the patients were followed for 4 years. The survival and the disease-free interval of
the cancer patients who had low AHH activity was significantly higher than that of the high AHH group. The
multivariate analysis with Cox's proportional hazad model showed primary tumour size, progesterone receptor
concentration, nodal status and log AHH to be the most important independent prognostic factors for
survival, while the occurrence of metastases, log AHH and tumour size were the equivalent factors for the
disease-free interval in primary breast cancers. We conclude that AHH activity may reflect the overall
malignant potential of breast cancer tissue.
The cytochrome P450-dependent monooxygenases play a key
role in the metabolism of a wide variety of xenobiotics, such
as drugs, environmental pollutants, carcinogens and also
steroids, including several chemotherapeutic agents used in
cancer treatment. Cytochrome P450 is found in animals and
in humans as multiple isoenzymes (Nebert & Conzalez,
1987), the relative amounts and activities of which may
largely govern the balance between bioactivation and
detoxification of a particular compound (Pelkonen & Nebert,
1982). Aryl hydrocarbon hydroxylase (AHH), a cytochrome
P450 activity induced by polycyclic aromatic hydrocarbons
(PAH), is considered the most important enzyme in the
metabolic activation of several compounds, especially PAH,
into ultimate carcinogenic forms (Pelkonen & Nebert, 1982).
The induction of AHH is genetically controlled by Ah-
receptors (Nebert & Gonzalez, 1987). In animal models,
levels of AHH activity are linked to susceptibility to chemical
carcinogen induced sarcomas, skin carcinomas, lung car-
cinomas, and lymphomas and leukaemias (Kouri et al.,
1982). Many efforts have been made to determine a relation-
ship between AHH activity or inducibility and susceptibility
to lung cancer or other forms of cancer also in human
populations, but the results vary and are mostly contradic-
tory (Kouri et al., 1982; Karki et al., 1987).
The actual cause of breast cancer is unknown. Probably it
is a multietiological as well as a multiform disease. Several
risk factors have been found, including genetic, hormonal,
nutritional, physical and morphological factors (Lynch et al.,
1984; Thomas, 1984; Mettlin, 1984). The development of
breast cancer, the occurrence of metastases and the survival
of patients vary from case to case. The role of chemical
carcinogenesis in human breast cancer is unclear. However,
in mice and rats, mammary tumours can be induced by
treatment with polycyclic aromatic hydrocarbons, such as
benzo(a)pyrene (BP) and 7,12-dimethylbenz(a)anthracene
(Furr & Jordan, 1984).
In the present study, we measured AHH activities in
benign and malign human breast tumours and compared the
results to the survival of patients and to the development of
the disease in 4-year follow-up time.
Materials and methods
Patients and samples
Breast samples were received from a total of 188 patients, 18
with benign breast tumour, 153 with primary breast car-
cinoma, and 17 with recurrent or new breast cancer at 1-23
years after the first mastectomy. The patients were operated
in 1983-84 in the University Hospital of Tampere or in
surrounding hospitals. The samples (0.5-2 g) were taken
primarily for a routine assay of oestrogen and progesterone
receptor content in the tumour tissue. They were placed in
small plastic bags, immediately frozen in liquid nitrogen and
brought to laboratory, where they were stored at - 70°C
until the day of steroid receptor assay, at which time the
microsomes were also prepared.
Data age, tumour size, metastatic axillary lymph nodes
and other metastases according to TNM classification
(Beahrs, 1984) of patients were recorded (Table I). All benign
tumour patients had fibrocystic disease. In the cancer patient
group, infiltrating ductal cancers accounted for 89% of the
primary and for 71% of recurrent cases, the remaining cases
being distributed among lobular, mucinous and medullary
histologic types.
Preparation of tumour cytosole and microsomes
The frozen samples were pulverised with a Braun dismem-
brator, suspended in cold 1O mM Tris-HCI buffer, pH 7.5,
containing 10% glycerol, and centrifuged at 105,000 g for 1 h
at + 4°C. The supernatants consisting of the cytosolic frac-
tion were used for steroid receptor determinations, whereas
the pellets were resuspended with a Potter-Elvehjelm glass-
teflon homogeniser in 0.1 M K-phosphate buffer, pH 7.4, and
recentrifuged at 13,000 g for Omin at + 4°C. The super-
natants contained the microsomal fractions and were used
for the AHH assay.
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Table I Preoperative characteristics of patients with benign breast
tumour (Group A), primary breast cancer (Group B) and recurrent
breast cancer for second mastectomy (Group C)
Group A Group B Group C
Number of patients 18 153 17
Age:
median, years 45 59 61
range 22-68 27-83 41 -72
TNM classification:
TI, No. 57 5
T2 61 6
T3 12 2
T4 20 3
unknown 3 1
NO 75 11
Ni 64 4
N2 9 1
N3 2 0
unknown 3 1
MO 149 16
Ml 4 0
unknown I
Steroid receptor assays
Both oestrogen (ER) and progesterone receptors (PR) of
breast cancer tissues were determined by the dextran charcoal
method (Koreman & Dukes, 1970). The oestrogen receptor
concentrations were considered positive (ER +) when they
contained 4 fmol mg-' protein or thatover, and negative
(ER -) when they were under that level. Progesterone recep-
tor concentrations were considered positive (PR +) when
they contained at least 7 fmol mg-' protein and negative
(PR -) when they contained less.
AHH assay
AHH activity in tumour microsomes was measured by the
fluorometric method (Nebert & Gelboin, 1968). The reaction
was carried out at 37C for 60 min in dark using 900p1 of
tumour microsomal suspension (0.2-4 mg proteinml-') in a
final incubation volume of I ml. An aliquot of every sample
suspension was boiled for 10min and assayed with samples
for individual blank correction. AHH activity is expressed as
fmol product (equivalent to 30H-BP) formed per mg protein
per min. The activity was considered to be detectable when
the difference of the active and the boiled sample fluorescence
intensity was twice as high as the variation in the duplicate
determination. This corresponds to 5 fmol mg-' protein
min-'. The protein concentration was determined according
to Peterson (1977) using bovine serum albumin as a stan-
dard.
Treatment andfollow-up ofpatients
All cancer patients were treated with mastectomy and, by
only a few exceptions, with evacuation of the same side
axillary lymph nodes. After the operation, the patients were
sent to an oncological unit, where radiation therapy was
given to all patients whose tumour size was TINIMO or
larger. Anti-oestrogens (tamoxifen) or cytotoxic drugs were
administered individually according to steroid receptor and
metastatic status (Table II). According to the routine treat-
ment schedule used in Finland, the patients thereafter visited
the oncological out-patient clinic every 3-6 months. The
relapses and deaths of patients were recorded, and the status
of patients exactly 4 years after the operation was used in
survival evaluation.
Statistics
Data processing was carried out on an Olivetti M280 com-
puter, and the appropriate statistics were obtained using
Table II Steroid receptors and anti-estrogen therapy of patients
with primary breast cancer (Group B) and recurrent breast cancer
for second mastectomy (Group C)
Group B Group C
Number of patients 153 17
Steroid receptor status:
ER-PR-, No. 35 5
ER-PR+ 16 4
ER+PR- 16 2
ER+PR+ 85 6
unknown 1
Oestrogen receptor concentration:
median 17 <2
range <2-655 <2-213
Progesterone receptor concentration:
median 36 <3
range <3-2632 <3-897
Anti-oestrogen therapy:
yes 74 11
no 76 6
unknown 3
SYSTAT package (Wilkinson, 1986), BMDP1L and
BMDP2L programme (Dixon, 1985). The differences between
the means were tested by the two-sample t-test or by one-way
analysis of variance followed by the Newman-Keuls test.
Also, Pearson correlation analysis and x2 test were per-
formed. The survival and disease-free interval curves were
constructed according to the Kaplan-Meier method. The
statistical differences between the curves were calculated
using log-rank test according to Mantel and Cox. The
relative importance of prognostic factors was assessed with
Cox's proportional hazard model. The proportionality
assumptions were tested using a time-dependent covariate.
Results
Overall characteristics andsurvival experience ofpatients
The median ages increased in our patient groups from
benign-tumour Group A to primary-cancer Group B and to
recurrent or second-cancer Group C (Table I), which fol-
lowed the development time ofthese diseases. The proportion
of small (Ti) and local (NO, MO) tumours was a little less in
the primary carcinoma group than in the recurrent car-
cinoma group, but the difference was not statistically
significant, because of the small size of Group C. The steroid
receptor status and receptor concentrations of breast cancer
patients (Group B and C) are given in Table II. In Group C,
there were less steroid receptor-positive (ER + PR +)
tumours than in Group B (X2 = 6.93, P <0.01), and the
medians and ranges of concentrations were lower.
At the end of the 4-year follow-up time after the surgical
operation, all patients with benign breast tumour (n = 18)
were disease-free. Of the primary cancer patients (n = 153),
83 were disease-free, but 70 patients had relapsed and
developed metastases during the follow-up time, and 38
patients of them died. Of the recurrent cancer group
(n = 17), nine patients were alive and eight dead after the
4-year follow-up from the second mastectomy.
AHH activities
The distributions of the AHH activities were wide and highly
skewed in all groups (Figure 1). The major part of AHH
activities in human breast tumour samples were very low;
about 10% were below the detection limit of the assay.
However, some malignant tumours showed over ten times
higher AHH activities compared to those of the benign
tumours.
Table III shows the medians and ranges of the AHH
activities of various patient groups and subgroups. Logarith-598 K. PYYKKO et al.
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Figure 1 The frequence distribution of AHH activities in
patients with benign breast tumour a, primary breast cancer b,
and recurrent breast cancer c.
mically transformed AHH activities were normally distri-
buted about the mean, which allows the analysis of variance.
The mean of log AHH in samples from benign tumours
differed significantly from those of cancer samples. The log
AHH activities of primary cancer patients who later on were
disease-free are significantly different from the values of those
who died. Differences between recurrent cases and disease-
free or dead patients were not statistically significant in
Group B. Among the recurrent cancer patients (Group C)
there was no prognostic difference between log AHHs of
living and deceased patients.
The primary cancer patients (n = 153) were divided into
three groups according to AHH activity as follows: the low
AHH group contained cases in which the AHH activity was
less than 24 fmol min- mg-' (n = 51), the medium AHH
group showed activities between 24 and 75 fmol min-' mg"'
(n = 50), and the high AHH group showed activities above
75 fmol min-' mg-' (n = 52). A clear prognostic difference
both in overall and in disease-free survival could be identified
between the groups (Figure 2). The survivals were poorer
when AHH activity was higher. The low-AHH group differed
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Figure 2 Overall survival curves (upper) and disease-free sur-
vival curves (lower) for 153 patients with primary breast cancer
by AHH activity in cancer tissue. The groups are: LOW (AHH
activity <24 fmol min-' mg-' protein, n = 51), MEDIUM (AHH
activity 24-75 fmol min-' mg-', n = 50) and HIGH (AHH
activity >75 fmol min' mg-', n =52). The significance of
difference in survival is given according to a Mantel-Cox test.
from the others, but the differences between medium and
high AHH groups were not statistically significant.
Relation to steroid receptor level and tumour stage
The AHH activities of primary breast cancer patients did not
correlate with the patient's age, the concentration of ER or
PR in tumour tissue, or T, N or M stage. Because no AHH
or ER or PR are normally distributed, their logarithms are
also included in the correlation analysis. Then the logarithm
of AHH activity correlated positively with increasing lymph
nodes (r = 0.238, P <0.01), and negatively with logarithm of
oestrogen receptor concentration (r = - 0.300, P <0.001)
and the logarithm of progesterone receptor concentration
(r = - 0.220, P <0.01). T, N and M-classes correlated with
each other.
Table III AHH activities in human breast tumours
Disease of AHH (fmolmg-'min-') log AHH Different
Group patient N Median Range Mean s.d. from groups'
A Benign tumours:
1- all 18 11 <5-37 0.833 0.590 2,3,4,5,6,7,8
B Primary cancers:
2 -all 153 34 <5-2683 1.564 0.666 1,5
3 -disease free 86 27 <5-488 1.425 0.651 1,5
4 -recurrent, alive 31 56 <5-614 1.597 0.669 1
5 -recurrent, dead 36 82 <5-2683 1.869 0.608 1,2,3
C Recurrent cancers:
6 -all 17 40 20-239 1.696 0.262 1
7 -alive 9 39 20-239 1.707 0.324 1
8 -dead 8 43 28-122 1.686 0.193 1
aDifferences between the log AHH of the groups were tested by variance analysis followed by Newman-Keuls test,
P <0.05.
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Multivariate analysis
In order to find out the relative importance and inde-
pendence of AHH activity as a prognostic factor, it was
tested in Cox's proportional hazard model together with
other factors whose prognostic significance was proposed.
The variables in the model included initially AHH activity
(fmol min-' mg-' protein) as well as its logarithm, the con-
centration of oestrogen and progesterone receptor
(fmol mg-'), axillary nodal status (coded: NO-I = 0, N2-
3 = 1), primary tumour size (coded: TI = 1, T2 = 2, T3 = 3,
T4 = 4), and distant metastases (coded: MO = 0, MI = 1).
The logarithm of AHH activity proved a better covariate
than untransformed AHH activity. The proportionality of
hazards assumption was tested and found to be valid. Table
IV summarises the results of stepwise selection procedures.
The most important independent prognostic factor for
overall survival in our primary breast cancer patients group
appeared to be tumour size, followed by progesterone recep-
tor concentration, nodal status and the logarithm of AHH
activity. The independent prognostic factors for disease-free
survival were the presence of metastases, the logarithm of
AHH activity and tumour size. Nodal status and steroid
receptors showed less independent impact on disease-free
survival prognosis.
Anti-oestrogen therapy
After mastectomy, about half of the primary carcinoma
patients were treated with anti-oestrogen (tamoxifen) (Table
II). Most of these patients (65/74) had cancer which TNM
class was over TINOMO, and 33 of them died during the
4-year follow-up time regardless of the therapy. As in the
whole cancer patient group, also in this subgroup signifi-
cantly more deaths occurred in the high AHH group than in
the low AHH group (X2 = 8.64, P <0.01). However, on the
basis of our results, it is not possible to separate the addi-
tional influence of the possibly increased anti-estrogen
metabolism from other factors affecting the distribution of
survivals in our patient material.
Discussion
The low activities and the wide variation of AHH activities
in human breast tumours found in the present work were
similar to those reported by Mason and Okey (1981). Large
interindividual variations in AHH activities were also found
in other human extrahepatic tissues, such as lung (Cohen et
al., 1979; Sabadie et al., 1981; Roberts et al., 1986), lympho-
cytes (Kellerman et al., 1973) and placenta (Gurtoo et al.,
1983). The wide distribution of AHH activities in tumour
samples may be due to a different basal level, a different level
of induction, a different response to inducers, or to a com-
bination of these factors. A cause for the highest activities
may be a genetic or a carcinogenesis-derived defect of the
regulation mechanism, which may lead to induction without
or regardless of inducer (Neber & Gonzalez, 1987).
Our main result, which is that high AHH activity in breast
cancer tissue predicts a bad prognosis of the disease, is a new
one. The AHH activity of benign tumours was significantly
lower than that in carcinomas and cancers with good prog-
nosis lower than that of bad prognosis (though there were
many individual exceptions). This suggests unavoidably the
possibility of AHH-mediated carcinogenic activation in the
most aggressive tumours.
Both higher and lower AHH activities in tumours com-
pared to normal tissue have been reported to occur in human
and chemically induced animal cancers. Human uterine
leiomyomas were reported to show higher cytochrome P450
activity than adjacent normal myometrium (Senler et al.,
1985b). In rat mammary tumours, higher AHH activities
were found than in normal nonlactating mammary tissue
(Mason & Okey, 1981), whereas in most of the lung cancer
patients, AHH activity was lower in the tumorous tissue than
in the surrounding tissue (Sebadie et al., 1981). The disc-
repancies of results probably indicate the difficulties to cont-
rol or to identify all the possible factors, as well as the
enormous heterogeneity of the various forms of cancers.
Animal experiments have shown that susceptibility to
several types of polycyclic aromatic hydrocarbon-induced
tumours is strongly associated with the Ah receptor-mediated
inducibility ofAHH (Pelkonen & Nebert, 1982). AHH induc-
tion has also been confirmed in human tissues. It is induced
in placenta by smoking (Pasanen et al., 1988b) and in cul-
tured lymphocytes by treatment with chemicals such as
bentz(a)antracene (Kouri et al., 1982; Kellerman et al., 1973).
Ah receptors were found in human tissues, and the induction
mechanism was considered to be the same as in mice and
rats. It has also been suggested that genetic differences in
AHH inducibility in humans might be important in determin-
ing susceptibility to some cancer forms (Kouri et al., 1982).
But again, the results from different laboratories vary. Kouri
et al. (1982) reported a positive correlation between high
AHH inducibility in cultures of human lymphocytes and the
occurrence of primary lung cancer, whereas Karki et al.
(1987) found no difference between the lung patients and the
controls. Also, no association was found between AHH
inducibility and occurrences of leukaemias or solid tumours
in children (Levine et al., 1984).
Our results do not confirm AHH-mediated chemical car-
cinogenesis in breast cancer, though it does not disprove it,
either. A considerable part of cancer samples and all benign
tumours showed very low AHH activity in our study as well
as in earlier ones (Mason & Okey, 1981). It is not probable
that AHH activity in those cases should have any import-
ance. The etiology of at least these tumours may be different
and independent of AHH. Several human cells in culture
have been shown to contain cytochrome P450 and exhibit
AHH induction in response to treatment to various com-
pounds. In a human breast cancer cell line, AHH activity
was induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD).
Different cell lines vary greatly with respect to the basal
expression levels of cytochrome P450 and its inducibility by
TCDD (Pasanen et al., 1988a). Some human breast tumour
cell lines, though derived from carcinomas, were practically
Table IV Importance of independent prognostic factors on disease-free survival
(A) and overall survival (B) of primary breast cancer patients (n = 153). Summary
of stepwise results of Cox's proportional hazard model
Step Factor Improvement Global
no. (variable entered) Chi-square P-value Chi-square P-value
A. Overall survival:
1 Tumour size 21.131 0.000 25.806 0.000
2 Procesterone receptors 17.744 0.000 30.612 0.000
3 Nodal status 9.479 0.002 56.652 0.000
4 Log AHH activity 7.058 0.008 62.939 0.000
B. Disease-free survival:
I Metastases 14.382 0.000 47.499 0.000
2 Log AHH activity 15.950 0.000 61.839 0.000
3 Tumour size 3.742 0.053 65.228 0.000600 K. PYYKKO et al.
non-responsive to induction (Pasanen et al., 1988a).
The present knowledge about the association of chemical
carcinogenesis to breast cancer mediated by AHH activity
seems not to be enough to give an answer to why high AHH
activity associates to a poor prognosis of breast cancer. A
clarification of its causes and importance will need much
further work. We do not know yet whether high AHH
activity is the cause or a consequence of malignant transfor-
mation. Also, it may be an independent change, which, how-
ever, is concentrated in the most serious breast cancer cases.
The most important prognostic indicator for breast cancer
have been found to be tumour size and the extent of axillary
lymph node involvement (Carter et al., 1989). Lymph node
status seems to serve as an indicator of a tumour's ability to
spread. Distant metastases are the cause of deaths in most
patients. In the present work, logarithm of AHH activity in
carcinomas correlated positively with the occurrence of axil-
lary lymph nodes. Tumour size, the presence of nodal and
distant metastases correlated with each other. The three most
important prognostic factors for disease-free intervals in our
primary breast cancer patients were found to be metastases,
log AHH and tumour size. For the overall survival, the
importance of nodal status and progesterone receptors were
also as a prognostic factors revealed, but log AHH still
included in the independent prognostic factors.
Some negative correlation after logarithm transformation
was found between AHH activity and steroid receptors. The
presence of oestrogen and progesterone receptors in breast
tumour increases the likelihood that the patient will respond
to endocrine therapy, but higher levels of oestrogen receptors
are associated with a greater probability of disease-free sur-
vival (Carter et al., 1989).
Because cytochrome P450 enzymes metabolise tamoxifen
as well as other anti-estrogens (Robinson & Jordan, 1988), a
high AHH activity may correlate with enzymes which in-
activate the chemotherapeutic agents within the tumour itself,
and may alter significantly the response of the tumour to the
drug (Senler et al., 1985a). This could explain the poor
prognosis of our high-AHH patients, who were treated with
antiestrogens. Because our patient material was too
heterogenous, the results did not give any clear confirmation
to this interesting possibility. However, the increased
metabolism of anti-oestrogens cannot explain all our results,
and a better clarification of this problem will be the aim for
our future studies.
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